Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Other Working Capital

Cash effect of changes in other operating assets and liabilities.

Seer, Inc.NASDAQ: SEER

Other Working Capital · Q1 FY2026 · quarter ended Mar 2026

Other working capital growth accelerates

Q1 FY2026 other working capital of $3.05M (cash outflow) rose 66.7% year over year, ahead of the -73.3% change in trailing-twelve-month other working capital. Sequentially, it rose 598.4% from the prior quarter.

Context

  • Other working capital amounted to 6.1% of revenue in FY2025, down 3.4 pp from a year earlier.
  • Other working capital increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +66.7% holds above the trailing-twelve-month pace of -73.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3.05M+598.4% QoQ
Last fiscal yearDec 2025
$983K+174.6% YoY
LTMMar 2026
-$235K-73.3% YoY
Other Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+66.7%——
1 year+174.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Other Working Capital history

USD · from the cash flow

Latest · FY2025
983K USD
Year-over-year change
+174.6%

Other Working Capital vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so other working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -73.3% is the 14th highest of 19, against a peer median of +71.1%.
  • Other working capital amounts to 1.6% of revenue for SEER, versus a peer median of 107.2%.
SEER Competitors
Other Working Capital for SEER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$86.82M USD+1322.1%—202.1%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$30.25M USD-1.6%+17.6%107.2%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$28.97M USD+104.7%+18.6%83.1%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$25.78M USD+176.9%+7.2%3.7%
KYMRKymera Therapeutics, Inc.LTM Jun 2026$25.52M USD-247.5%—24.3%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$13.47M USD+234.3%+8.5%—
PEPGPepGen Inc.LTM Mar 2026$11.31M USD-262.2%——
PHVSPharvaris N.V.LTM Sep 2026€8.94M EUR+39.2%-0.4%—
SANASana Biotechnology, Inc.LTM Mar 2026$6.9M USD+146.4%——
QSIQuantum-Si incorporatedLTM Mar 2026$6.17M USD+1572.6%—333.3%
LYELLyell Immunopharma, Inc.LTM Mar 2026$3.12M USD-33.0%-55.0%10071.0%
NKTXNkarta, Inc.LTM Mar 2026$1.55M USD-80.6%——
STTKShattuck Labs, Inc.LTM Mar 2026$1.39M USD-137.3%-34.0%138.6%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$1.3M USD+117.0%+55.4%—
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$1.22M USD-58.4%-27.8%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$526K USD-126.6%+20.2%—
SEERSeer, Inc.LTM Mar 2026$235K USD-73.3%—1.6%
MOLNMolecular Partners AGLTM Mar 2026CHF 102.77K CHF+103.1%——
MNOVMediciNova, Inc.LTM Mar 2026$86.96K USD+117.1%+417.4%14.6%
Peer median (excluding SEER) —+71.1%+8.5%107.2%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(71.17M)(92.97M)(86.28M)(86.6M)(73.6M)
Depreciation & Amortization2.56M3.94M5.58M6.18M7.25M
Deferred Income Tax1.2M0000
Stock-Based Compensation25.93M33.67M34.42M28.21M15.41M
Change in Working Capital(5.87M)(7.09M)(2.72M)(144K)(579K)
Accounts Receivables(2.5M)(2.87M)302K487K277K
Inventory(3.59M)(1.59M)(1.95M)(2.67M)(2.9M)
Accounts Payables1.6M(1.55M)(987K)3.36M1.06M
Other Working Capital(1.38M)(1.07M)(91K)(1.32M)983K
Other Non-Cash Items1.01M1.66M(10.07M)6.25M7.07M
Operating Cash Flow(46.35M)(60.78M)(59.07M)(46.11M)(44.45M)
Capital Expenditures(6.92M)(10.27M)(7.31M)(3.58M)(1.8M)
Acquisitions (Net)163.96M0000
Purchases of Investments(279.96M)(366.27M)(403.09M)(272.93M)(173.17M)
Sales of Investments116M253.65M448.31M342.03M237.81M
Other Investing Activities(163.96M)170K0343K(1.3M)
Investing Cash Flow(170.88M)(122.72M)37.9M65.86M61.55M
Debt Repayment00000
Common Stock Issued102.96M000458K
Common Stock Repurchased(35K)(20K)(13K)(11.82M)(10.2M)
Dividends Paid00000
Other Financing Activities13.71M3.91M465K321K(827K)
Financing Cash Flow116.63M3.89M452K(11.5M)(10.57M)
Effect of Forex Changes00000
Net Change in Cash(100.59M)(179.61M)(20.71M)8.25M6.53M
Free Cash Flow(53.27M)(71.05M)(66.37M)(49.69M)(46.25M)

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.